On February 26, 2026, Boehringer Ingelheim secured an exclusive global license for a preclinical small-molecule inhibitor program from Sitryx Therapeutics. The collaboration focuses on developing novel, potentially disease-modifying oral treatments for a range of autoimmune and inflammatory diseases, addressing the significant unmet needs of patients who do not achieve long-term control with current therapies.
Under the agreement, Boehringer assumes full responsibility for the continued research, clinical development, and eventual commercialization of the licensed candidates. In return, Sitryx is set to receive upfront and near-term payments, with potential development, regulatory, and commercial milestones totaling more than $500 million, plus tiered royalties on future global sales.
The program utilizes a precision immunometabolic approach, targeting specific pathways to restore immune balance. Meanwhile, Sitryx is independently advancing its lead candidate, SYX-5219—a potentially first-in-class oral PKM2 modulator. Currently in Phase 1b trials for atopic dermatitis, SYX-5219 has already demonstrated a favorable safety profile and robust reduction in key inflammatory biomarkers during initial testing in healthy volunteers.